Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kyle Tokarz

Pain Medicine Dartmouth, MA Doctor of Osteopathy

NPI 1649242637 CMS profile 347294

535 Faunce Corner Rd, Dartmouth, MA 02747

Open in the dashboard

General payments

$1,035

44 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kyle Tokarz of Dartmouth, MA is reported in the CMS Open Payments database as having received $1,035 across 44 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 35th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $19 1
2024 General $60 3
2023 General $710 29
2022 General $102 5
2021 General $20 1
2020 General $69 3
2019 General $56 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kyle Tokarz
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Kyle Tokarz were reported at $19. Among 757 Pain Medicine profiles paid that year, the median was $470 and the middle half received between $146 and $1,462.

Show as a table
Year Kyle Tokarz Pain Medicine median Middle half National median
2019 $56 $506 $144–$1,566 $163
2020 $69 $315 $96–$934 $114
2021 $20 $452 $134–$1,237 $132
2022 $102 $475 $124–$1,407 $149
2023 $710 $480 $136–$1,384 $160
2024 $60 $521 $164–$1,511 $164
2025 $19 $470 $146–$1,462 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $415 17 payments
  2. Abbott Laboratories $117 4 payments
  3. Teva Pharmaceuticals USA, Inc. $92 5 payments
  4. Nevro Corp. $81 4 payments
  5. UCB, Inc. $64 2 payments
  6. Pfizer Inc. $47 2 payments
  7. Stimwave Technologies Incorporated $40 2 payments
  8. DePuy Synthes Sales Inc. $34 1 payment
  9. CSL Behring $30 1 payment
  10. Argenx US, Inc. $24 1 payment
  11. Other $90 5 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,035 44 payments
Products named General payments · program years 2019–2025
  1. UBRELVY $272 12 payments
  2. QULIPTA $143 5 payments
  3. Proclaim Family of SCS IPGs $93 3 payments
  4. AUSTEDO $52 3 payments
  5. Senza $49 2 payments
  6. NURTEC ODT $47 2 payments
  7. PAXLOVID $47 2 payments
  8. Austedo XR $40 2 payments
  9. VIPER $34 1 payment
  10. Sentio $34 1 payment
  11. Other $463 23 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 42 drugs

Part D claims

5,839

Median for Pain Management: 951

Drug cost

$303,060

Median for Pain Management: $26,034

Branded share of claims

23.3%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycontin Oxycodone Hcl Brand 148 $80,459
Xtampza Er Oxycodone Myristate Brand 48 $35,299
Nucynta Tapentadol Hcl Brand 29 $24,575
Buprenorphine Generic 68 $17,222
Nucynta Er Tapentadol Hcl Brand 14 $16,570
Belbuca Buprenorphine Hcl Brand 23 $14,460
Gabapentin Generic 778 $13,920
Lidocaine Generic 116 $10,704
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 351 $8,205
Movantik Naloxegol Oxalate Brand 17 $6,797

The 10 drugs with the highest cost, of 42 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 43 billing codes

Paid by Medicare

$213,334

Of which drugs: $645

Medicare patients

446

Average age 71

Services billed

2,559

280 women, 166 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 39%
Diabetes 29%
COPD 27%
Ischemic heart disease 26%
Chronic kidney disease 26%
Osteoporosis 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

44 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record